<DOC>
	<DOCNO>NCT00004646</DOCNO>
	<brief_summary>OBJECTIVES : I . Characterize effect prednisone muscle protein metabolism patient Duchenne muscular dystrophy . II . Determine whether prednisone change level insulin-like growth factor 1 , growth hormone , insulin . III . Characterize effect prednisone muscle morphometry muscle localization utrophin . IV . Compare prednisone response patient Duchenne muscular dystrophy see normal individual patient facioscapulohumeral dystrophy .</brief_summary>
	<brief_title>Phase III Randomized , Double-Blind Study Prednisone Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients randomly assign prednisone placebo . Therapy administer daily 12 week ; prednisone taper .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Ambulatory male Duchenne muscular dystrophy No medical/psychiatric contraindication protocol therapy No requirement regular use prescription medication</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>muscular dystrophy</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>